iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
August 07, 2019 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference Gosselies, Belgium and Cambridge, MA – August 7, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics to Present at UBS Global Healthcare Conference
May 13, 2019 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at UBS Global Healthcare Conference Gosselies, Belgium and Cambridge, MA – May 13, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel...
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer
April 17, 2019 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer First cohort of patients with advanced cancer now...
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer
April 17, 2019 02:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer First cohort of patients with advanced cancer now...
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
March 29, 2019 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019 Gosselies, Belgium and...
iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer
March 26, 2019 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer Gosselies, Belgium and Cambridge, MA – March 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in March
March 05, 2019 08:30 ET
|
iTeos Therapeutics SA
Gosselies, Belgium - March 5, 2019 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of...
iTeos Therapeutics to Participate in Upcoming Conferences in November
November 07, 2018 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Participate in Upcoming Conferences in November Gosselies, Belgium – November 7, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies,...
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting
November 06, 2018 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September
August 29, 2018 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September Gosselies, Belgium – August 29, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer...